Statin use is associated with a reduced incidence of colorectal cancer expressing SMAD4.
Br J Cancer
; 126(2): 297-301, 2022 02.
Article
em En
| MEDLINE
| ID: mdl-34703008
ABSTRACT
BACKGROUND:
Long-term use of statins is associated with a small reduced risk of colorectal cancer but their mechanism of action is not well understood. While they are generally believed to act on KRAS, we have previously proposed that they act via influencing the BMP pathway. The objective of this study was to look for associations between statin use and the risk of developing colorectal cancer of a particular molecular subtype.METHODS:
By linking two registries unique to the Netherlands, 69,272 statin users and 94,753 controls were identified and, if they developed colorectal cancer, their specimens traced. Colorectal cancers were molecularly subtyped according to the expression of SMAD4 and the mutation status of KRAS and BRAF.RESULTS:
Statin use was associated with a reduction in the risk of developing colorectal cancer regardless of molecular subtype (HR 0.77; 95% CI 0.66-0.89) and a larger reduction in the risk of developing SMAD4-positive colorectal cancer (OR 0.64; 95% CI 0.42-0.82). There was no relationship between statin use and the risk of developing colorectal cancer with a mutation in KRAS and/or BRAF.CONCLUSIONS:
Statin use is associated with a reduced risk of developing colorectal cancer with intact SMAD4 expression.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Colorretais
/
Biomarcadores Tumorais
/
Proteínas Proto-Oncogênicas p21(ras)
/
Inibidores de Hidroximetilglutaril-CoA Redutases
/
Proteínas Proto-Oncogênicas B-raf
/
Proteína Smad4
/
Mutação
Tipo de estudo:
Incidence_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Female
/
Humans
/
Male
/
Middle aged
País/Região como assunto:
Europa
Idioma:
En
Revista:
Br J Cancer
Ano de publicação:
2022
Tipo de documento:
Article